Showing results (131-140 of 230) with videos related to
Sort By:
Pageof 23
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2011
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PETBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.Cancer Research|February 17, 2017
[18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase InhibitionRong Zhou, Austin R Pantel, Shihong Li, et al.American Journal of Nuclear Medicine and Molecular Imaging|April 13, 2016
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancerChristine E Edmonds, Mehran Makvandi, Brian P Lieberman, et al.Cancer|January 8, 2005
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survivalLisa K Dunnwald, Julie R Gralow, Georgiana K Ellis, et al.Head & Neck|February 14, 2006
Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expressionRobert C Rostomily, Maria Elias, Mei Deng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2016
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast CancerBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.Academic Radiology|September 16, 2008
Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancerPeter R Eby, Savannah C Partridge, Steven W White, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.Breast Cancer Research : BCR|February 18, 2025
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancerNatasha B Hunter, Lanell M Peterson, Jennifer M Specht, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matterAlexander M Spence, Mark Muzi, David A Mankoff, et al.Pageof 23